Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03238300 · ClinicalTrials.gov registry record · Phase 2

Neuroscience-Informed Treatment Development for Adolescent Alcohol Use

A Phase 2 study of Alcohol Drinking and Control, sponsored by Medical University of South Carolina.

Completed
Registry status
Phase 2
Development phase
57
Enrollment target
1
Study location

NCT03238300: Completed Phase 2 study of Alcohol Drinking and Control, sponsored by Medical University of South Carolina.

NCT03238300 is a Phase 2 study of Alcohol Drinking and Control that has completed, run by Medical University of South Carolina. The registered enrollment target is 57 participants, below the 630-participant average among 85 other Alcohol Drinking trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03238300, a Phase 2 study of Alcohol Drinking and Control, has completed, sponsored by Medical University of South Carolina.

COMPLETED
Registry status
Phase 2
Development phase
57 participants
Enrollment target
1
Study location

Study Summary

This study will examine the effect of N-Acetylcysteine (NAC), an over-the-counter antioxidant supplement, on brains of youth (ages 15-19) using magnetic resonance imaging (MRI).

Primary Outcome

Using magnetic resonance spectroscopy and a within-subjects design, we will determine the effect of N-Acetylcysteine versus placebo on modulating anterior cingulate glutamate levels in adolescents. Values provided are absolute values (mmol/kg) at the end of each intervention period. Due to complexities of this method, "normal" levels of glutamate are not known; thus, we cannot make conclusions about the meaning of "higher" or "lower" glutamate levels when comparing N-acetylcysteine to placebo.

Conditions Studied

Interventions

  • DRUG Placebo Oral Capsule
  • DRUG N-Acetylcysteine

Study Locations (1)

South Carolina

  • Medical University of South Carolina - Charleston

Trial Details

FieldValue
Enrollment Target 57 participants
Start Date 2017-10-16
Est. Completion 2022-03-01
Phase Phase 2

What the finished NCT03238300 record still lists

NCT03238300 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 57 participants, a relatively small participant target, below the 630-participant average among 85 other Alcohol Drinking trials with a reported enrollment target (91% lower).

The record links to 2 conditions, with Alcohol Drinking appearing as the primary indexed condition, and to 2 interventions - of which Placebo Oral Capsule is the first listed.

NCT03238300 reports a single indexed study location in South Carolina.

Frequently Asked Questions

What is clinical trial NCT03238300 about?

NCT03238300 is a clinical study titled "Neuroscience-Informed Treatment Development for Adolescent Alcohol Use". This study will examine the effect of N-Acetylcysteine (NAC), an over-the-counter antioxidant supplement, on brains of youth (ages 15-19) using magnetic resonance imaging (MRI).

What is the current status of trial NCT03238300?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 57 participants. The study started on 2017-10-16. Estimated completion is 2022-03-01.

What conditions does trial NCT03238300 study?

This clinical trial studies the following conditions: Alcohol Drinking, Control.

What interventions are being tested in trial NCT03238300?

The interventions under investigation include: Placebo Oral Capsule (DRUG), N-Acetylcysteine (DRUG).

Who is sponsoring clinical trial NCT03238300?

This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03238300 being conducted?

This trial has 1 study location across South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Alcohol Drinking

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03238300's enrollment target sits among peer trials

57 67th of 85 higher than 19 of 85 other Alcohol Drinking trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Alcohol Drinking trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03521830 · 57 participants · Phase 2

    Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma

  • NCT03587701 · 57 participants · Phase 2

    Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease

  • NCT04104126 · 57 participants · NA

    Blood Flow Restriction Therapy in Achilles Injury

  • NCT04703842 · 57 participants · Phase 1

    Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03238300, the US trial registry maintained by the National Library of Medicine. NCT03238300 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.